Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Assets Average (2016 - 2025)

Ironwood Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $396.5 million for Q4 2025.

  • For Q4 2025, Assets Average rose 7.1% year-over-year to $396.5 million; the TTM value through Dec 2025 reached $396.5 million, up 7.1%, while the annual FY2025 figure was $373.9 million, 9.02% down from the prior year.
  • Assets Average for Q4 2025 was $396.5 million at Ironwood Pharmaceuticals, up from $369.5 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.1 billion in Q1 2023 and bottomed at $335.1 million in Q2 2025.
  • The 5-year median for Assets Average is $571.5 million (2021), against an average of $694.3 million.
  • The largest annual shift saw Assets Average soared 122.96% in 2021 before it plummeted 59.66% in 2024.
  • A 5-year view of Assets Average shows it stood at $1.1 billion in 2021, then dropped by 2.97% to $1.1 billion in 2022, then tumbled by 53.52% to $497.6 million in 2023, then dropped by 25.6% to $370.2 million in 2024, then grew by 7.1% to $396.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Assets Average are $396.5 million (Q4 2025), $369.5 million (Q3 2025), and $335.1 million (Q2 2025).